Jamie Cresto

The mature #hypertension market has several long-established therapies and plenty of branded and generic competition. Read the #MarketAccess review by MMIT's Jacquie Eckrote: https://ow.ly/aIvs50RAUQs.

4

The mature #hypertension market has several long-established therapies and plenty of branded and generic competition. Read the #MarketAccess review by MMIT's Jacquie Eckrote: https://ow.ly/A0sF50RAURP.

12

The mature #hypertension market has several long-established therapies and plenty of branded and generic competition. Read the #MarketAccess review by MMIT's Jacquie Eckrote: https://ow.ly/YEwq50RAZnz.

2

Biosimilars might be the life raft you need! 🆘 Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, breaks down innovative treatments that can deliver high-quality cancer care WITHOUT breaking the bank. She discusses: *US biologics market growing 12.5% annually over the past 5 years *Biologics projected to be 55% of the top 100 medications used in the US by 2026! *Areas she focuses on to promote biosimilars in her practice  *Adoption of clinical management programs  *PBM contract negotiations To read the full article:  https://lnkd.in/ePiXXK-q

2

#DidYouKnow that biosimilars are one of the fastest-growing classes of medications, with no clinically meaningful differences from originator biologics? ⤵️ #Biosimilars are safe and as effective as the originator biologic, and, on average, less expensive than their brand-name counterpart. Cordavis™️, a CVS Healthspire™️ company, works directly with manufacturers to bring these innovative medicines to market. We’ve seen exciting early market results from Cordavis’ first product, Hyrimoz, a Humira biosimilar brought to market with Sandoz with a list price more than 80% lower than Humira’s list price at time of launch. Learn more from our Chief Medical Officer, Dr. Sreekanth Chaguturu: https://cvs.co/44omQqO

173

7 Comments

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why? An analysis by Avalere finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers. Despite years of demonstrated savings and price deflation, the #Medicare program has allowed drug plans to make changes over the last 10 years that require patients to pay more for many generic drugs even as the prices of those drugs have fallen. Simple formulary reforms that place generic drugs on existing generic tiers can level the playing field by prioritizing coverage decisions and by nudging Medicare plans and #PBMs towards patient-centric choices. Read AAM’s blog here: https://lnkd.in/ezyvPkvZ

12

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

3

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

1

BioPharma Dive highlights Spherix's research regarding physician reluctance to trade brand-name biologics for biosimilars.    Despite prescriber sentiments, an upcoming change in the Medicare Part D benefit, where Medicare plans will cover a larger portion of the cost, may influence changes in coverage, creating a closer alignment with biosimilars to lower the overall cost of treatments.   Learn more about the influence biosimilars is having in the Humira markets here: https://lnkd.in/ebtxithp   #Humira #adalimumab #Biosimilars #BiopharmaDive

17

❗ICYMI❗ Glucagon-like peptide-1 receptor agonists 💊 or #GLP1 medications, have been center stage in the discussion around the treatment of type 2 #diabetes and weight loss. With increased usage of these products, it is crucial for #plansponsors to have a solid cost-containment strategy in this space. 💵 ProAct can help: https://hubs.li/Q02tcWrL0

9

🌟 Proud of the robust efforts of our members in New Mexico on the path to eliminating hepatitis C ! 👩‍⚕️💊 From innovative treatment programs to community outreach initiatives, New Mexico is leading the charge in eliminating #HCV and improving public health outcomes, largely without federal support. Check out this article from The New York Times to learn how the New Mexico Department of Health is making a difference in public health―despite a nationwide elimination plan, still out of reach: https://lnkd.in/gDDykWPR 

1

The #AdherencePackaging market is expected to reach $1.1 billion by 2026, driven by #pharmacies recognizing the importance of #MedicationAdherence. That’s why upgrading to the Axial® Multi/Unit-Dose #PouchPackager just makes sense! And thanks to #Section179 of the tax code, you can deduct the full purchase price from your gross income immediately, offering up to $45,000 in savings for #pharmacies. https://lnkd.in/gudfd7FS

3